Shots:
Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms
Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab
With this acquisition, Genmab…
Dedication, a go-getter attitude, and perseverance kept pushing PharmaShots to unlock new achievements now and then. Today, PharmaShots turns six
Started as a news-delivering platform, PharmaShots has evolved over the years as a branding partner to several life sciences companies
We appreciate your unwavering support that kept motivated us and making headway in our journey…
Shots:
Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF
Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta
Sutro is now enrolling patients for the…
Shots:
The EMA granted Positive Opinion to 4 Biologics and 3 New Chemical Entities in June 2024, leading to treatments for patients and advances in the healthcare industry
The major highlighted drugs were Merck’s Winrevair to treat Pulmonary Arterial Hypertension (PAH) and Roche’s PiaSky for Paroxysmal Nocturnal Haemoglobinuria (PNH)
PharmaShots has compiled a list of 5 drugs that…
Shots:
Small cell lung cancer (SCLC) aka Oat cell carcinoma is a rare & fast-growing lung cancer and ~15% of bronchogenic carcinomas are SCLC
In this reprise of our Disease of the Month report, we bring an illuminating account of SCLC with a dive analysis of epidemiology, market size, disease management, available therapies, patient advocacy…
Shots:
Backed with an evergreen investment strategy, Invus makes investments across several company stages ranging from early growth to turnarounds
In 2023, Invus participated in 6 investment rounds in around 29 companies focusing on biopharma, manufacturing & services, and devices
For a curated report on a specific investor or venture capital, reach out to us…
Shots:
Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M
KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation …
In June, PharmaShots was busy covering the heavy influx of life science updates. Our most-read Top 20 reports covered Nutraceutical and Innovative Digital Therapeutics companies. For the Disease of the Month report, we covered Fabry Disease. The Know Your Investor report featured a condensed report on Google Ventures.
Like every Month, we published reports on Biosimilars, Designations, FDAand EMA approvals.
In August, PharmaShots will…
Shots:
2023 had been a great year for the biopharma industry despite several imposed restrictions from the IRA and inflation
With several swaying factors impacting the biopharma industry, including social, economic, regulatory and others, some of the noteworthy trends that emerged in 2024 and are shaping the ways biopharma companies operate
The article explores four key…
With great zeal, PharmaShots began an Exclusive Video Interview series for C-suites. An innovative idea to bring thought leaders of the industry, our Exclusive Video Interview offering is a noble initiative by PharmaShots to capture the developments of leading companies. As a part of offering, PharmaShots will be publishing exclusive video interviews every second Monday…

